What does it mean to #BeFierce? Our new look tells the story

FiercePharma Logo

A few years ago, one of our Fierce Life Sciences editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked. It was a glancing reference, but the comment stuck, and for good reason. We had never articulated, for ourselves or anyone else, what being Fierce actually meant.

Today, we are. I am pleased to introduce to you a new look for Fierce Life Sciences that exemplifies our bold, forward-thinking approach to everything we do here. It marks a new and improved destination not only for news and analysis you can’t get anywhere else, but for events that delve deeply into the biopharma universe.

Our websites may be most familiar to you as a reader, but our sister company, ExL, has produced a full slate of educational events for years. Now, we’re all Fierce. We’re merging our news and event brands to bring you greater access to information, education, inspiration and new connections.

That’s why our new look extends across our websites, newsletters and events—to show the combined might of Fierce Life Sciences. With our coverage from preclinical research to market and beyond, we now reach a community of 500,000 subscribers and attendees.

We’re excited to debut this merger. For an overview of our new brands and offerings, please visit www.fiercelifesciences.com. Take a spin through the sites and let me know what you think.

What isn’t changing? Our commitment to editorial independence and quality, and our engaging, content-driven conferences that attract decisionmakers across the biopharma and healthcare communities. We’re proud to bring you Fierce insights and connections everywhere you need us to be.

As always, thank you for reading and thank you for being a part of the Fierce community. #BeFierce.  – Rebecca Willumson (email | Twitter) 

WeAreFierce

Suggested Articles

Bayer has withdrawn part of a proposed Roundup settlement after a judge questioned how it's handling potential future claims.

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

The CEOs for COVID-19 vaccine partners Pfizer and BioNTech are sounding confident in their program as they gear up for phase 3.